ChABC-loaded PLGA nanoparticles: A comprehensive study on biocompatibility, functional recovery, and axonal regeneration in animal model of spinal cord injury

Azizi, Monireh; Farahmandghavi, Farhid; Joghataei, Mohammad Taghi; Zandi, Mojgan; Imani, Mohammad; Bakhtiari, Mitra; Omidian, Hossein

doi:10.1016/j.ijpharm.2020.119037

Cited by 26 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, some stabilizing interface-active excipients such as sugars (trehalose, sorbitol) are added into the internal water phase solution that are able to protect proteins from aggregation as well as from denaturation during emulsification process (Han et al 2016;Ma 2014). Recently, Azizi et al (2020) applied this technique to produce W/O/W PLGA nanoparticles loading chondroitinase ABC (ChABC), a bacterial enzyme used to digest the chondroitin sulfate proteoglycans (CSPGs) to contrast the spinal cord injury (SCI).…”

Section: Double Emulsionmentioning

confidence: 99%

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

et al. 2020

View full text Add to dashboard Cite

Polymeric microparticles (MPs) are recognized as very popular carriers to increase the bioavailability and bio-distribution of both lipophilic and hydrophilic drugs. Among different kinds of polymers, poly-(lactic-co-glycolic acid) (PLGA) is one of the most accepted materials for this purpose, because of its biodegradability (due to the presence of ester linkages that are degraded by hydrolysis in aqueous environments) and safety (PLGA is a Food and Drug Administration (FDA)-approved compound). Moreover, its biodegradability depends on the number of glycolide units present in the structure, indeed, lower glycol content results in an increased degradation time and conversely a higher monomer unit number results in a decreased time. Due to this feature, it is possible to design and fabricate MPs with a programmable and time-controlled drug release. Many approaches and procedures can be used to prepare MPs. The chosen fabrication methodology influences size, stability, entrapment efficiency, and MPs release kinetics. For example, lipophilic drugs as chemotherapeutic agents (doxorubicin), anti-inflammatory non-steroidal (indomethacin), and nutraceuticals (curcumin) were successfully encapsulated in MPs prepared by single emulsion technique, while water-soluble compounds, such as aptamer, peptides and proteins, involved the use of double emulsion systems to provide a hydrophilic compartment and prevent molecular degradation. The purpose of this review is to provide an overview about the preparation and characterization of drug-loaded PLGA MPs obtained by single, double emulsion and microfluidic techniques, and their current applications in the pharmaceutical industry. Graphic abstract

show abstract

Section: Double Emulsionmentioning

confidence: 99%

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…More recently, it was shown that the use of iron oxide nanoparticles along with electromagnetic fields induced sprouting from mature neurons and axons, significantly less demyelination and more myelinated fibers in injured rats [101]. Other factors such as neurotrophins [102,103] and the enzyme chABC [104], which has already been seen as a promising treatment for SCI, have been loaded in NPs, showing that they can induce axon regrowth with a controlled and sustained release at the site of the lesion.…”

Section: Nanoparticlesmentioning

confidence: 99%

Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach

Bordoni

Scarian

Rey

et al. 2020

IJMS

View full text Add to dashboard Cite

Neurodegenerative disorders (i.e., Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and spinal cord injury) represent a great problem worldwide and are becoming prevalent because of the increasing average age of the population. Despite many studies having focused on their etiopathology, the exact cause of these diseases is still unknown and until now, there are only symptomatic treatments. Biomaterials have become important not only for the study of disease pathogenesis, but also for their application in regenerative medicine. The great advantages provided by biomaterials are their ability to mimic the environment of the extracellular matrix and to allow the growth of different types of cells. Biomaterials can be used as supporting material for cell proliferation to be transplanted and as vectors to deliver many active molecules for the treatments of neurodegenerative disorders. In this review, we aim to report the potentiality of biomaterials (i.e., hydrogels, nanoparticles, self-assembling peptides, nanofibers and carbon-based nanomaterials) by analyzing their use in the regeneration of neural and glial cells their role in axon outgrowth. Although further studies are needed for their use in humans, the promising results obtained by several groups leads us to suppose that biomaterials represent a potential therapeutic approach for the treatments of neurodegenerative disorders.

show abstract

“…PLGA fibers promote axonal regeneration and when associated with drugs or growth factors, improve motor function. [72][73][74][75] PCL is a polymer that presents a more lengthy degradation cycle, allowing it to be implemented as a scaffold for cell transplantation and for better integration of the transplanted cells in the host tissue. 63 Some of the studies applied coaxial electrospinning, which is one of the most successful technologies for incorporating biomolecules in scaffolds.…”

Section: Electrospun Scaffoldsmentioning

confidence: 99%

Nanotechnology for the Treatment of Spinal Cord Injury

Zimmermann

Alves

Sperling

et al. 2021

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Spinal cord injury (SCI) affects the central nervous system (CNS) and there is currently no treatment with the potential for rehabilitation. Although several clinical treatments have been developed, they are still at an early stage and have not shown success in repairing the broken fiber, which prevents cellular regeneration and integral restoration of motor and sensory functions. Considering the importance of nanotechnology and tissue engineering for neural tissue injuries, this review focuses on the latest advances in nanotechnology for SCI treatment and tissue repair. The PubMed database was used for the bibliographic survey. Initial research using the following keywords ''tissue engineering and spinal cord injury'' revealed 970 articles published in the last 10 years. The articles were further analyzed, excluding those not related to SCI or with results that did not pertain to the field of interest, including the reviews. It was observed that a total of 811 original articles used the quoted keywords. When the word ''treatment'' was added, 662 articles were found and among them, 529 were original ones. Finally, when the keywords ''Nanotechnology and spinal cord injury'' were used, 102 articles were found, 65 being original articles. A search concerning the biomaterials used for SCI found 700 articles with 589 original articles. A total of 107 articles were included in the discussion of this review and some are used for the theoretical framework. Recent progress in nanotechnology and tissue engineering has shown promise for repairing CNS damage. A variety of in vivo animal testing for SCI has been used with or without cells and some of these in vivo studies have shown successful results. However, there is no translation to humans using nanotechnology for SCI treatment, although there is one ongoing trial that employs a tissue engineering approach, among other technologies. The first human surgical scaffold implantation will elucidate the possibility of this use for further clinical trials. This review concludes that even though tissue engineering and nanotechnology are being investigated as a possibility for SCI treatment, tests with humans are still in the theoretical stage.

show abstract

ChABC-loaded PLGA nanoparticles: A comprehensive study on biocompatibility, functional recovery, and axonal regeneration in animal model of spinal cord injury

Cited by 26 publications

References 46 publications

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

Recent advances in the formulation of PLGA microparticles for controlled drug delivery

Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach

Nanotechnology for the Treatment of Spinal Cord Injury

Contact Info

Product

Resources

About